Details for Patent: 7,470,698

Title:	Adenosine A3 receptor modulators
Abstract:	The compounds of the following formula: ##STR00001## wherein R, R.sup.2, R.sup.3 and A have the meanings given in the specification, are endowed with selective A.sub.3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A.sub.3 receptor, or can be used in a diagnostic application to determine the relative binding of other compounds to the A.sub.3 receptor. The compounds can be labeled, for example with fluorescent or radiolabels, and the labels used in vivo or in vitro to determine the presence of tumor cells which possess a high concentration of adenosine A.sub.3 receptors.
Inventor(s):	Baraldi; Pier Giovanni (Ferrara, IT), Borea; Pier Andrea (Ferrara, IT)
Assignee:	King Pharmaceuticals Research and Development, Inc. (Cary, NC)
Filing Date:	Jul 09, 2007
Application Number:	11/774,784
Claims:	1. The compound of the formula ##STR00023## or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1, wherein the pharmaceutically acceptable salt thereof is the hydrochloride salt. 3. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 4. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.